We traveled to Kansas City, Missouri, for a State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, which focused on recent progress made in squamous NSCLC and small cell lung cancer, provided tips on how to navigate the complex paradigm of oncogene-driven disease, and shed light on emerging biomarkers in the space.
We traveled to Memphis, Tennessee for a State of the Science Summit™ on Genitourinary Cancers, which focused on advances made in the treatment landscapes of metastatic renal cell carcinoma and prostate cancer.
We traveled to New York, New York, for a State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, which focused on topics ranging from surgical techniques, to headway made in immunotherapy, to emerging biomarkers, to diagnostic advancements.
We traveled to Minneapolis, Minnesota, for a State of the Science Summit on Breast Cancer, which focused on surgical approaches for node-positive breast cancer, the use of CDK4/6 inhibitors in hormone receptor–positive disease, and emerging drug therapies in triple-negative disease.
We traveled to Syracuse, New York, for a State of the Science Summit on Advanced Non–Small Cell Lung Cancer, which focused on practice-change clinical trials in the space, as well as novel approaches to treatment with checkpoint inhibitors, targeted therapies, radiation, and minimally invasive surgery.
We traveled to New York City, New York, for a State of the Science Summit on Multiple Myeloma, which focused on stem cell transplant, minimal residual disease, maintenance options, and treatment approaches for newly diagnosed myeloma.
We traveled to Washington D.C. for a State of the Science Summit on Breast Cancer, which focused on additional recent advances in the NSCLC and small cell lung cancer paradigms, touching on TKIs, immunotherapy, and other investigational agents.
We traveled to Pittsburgh, Pennsylvania for a State of the Science Summit on Breast Cancer, which focused on novel approaches in metastatic triple-negative breast cancer and treatment strategies for patients with brain metastases.
We traveled to San Diego, California, for the 2018 ASH Annual Meeting, where we spoke with several experts across hematologic malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma.
We headed to San Antonio, Texas, for the San Antonio Breast Cancer Symposium, where we spoke to several principal investigators who detailed new applications of novel therapies, surgical intervention strategies, and lifestyle modifications.